Literature DB >> 24336783

Guideline adherence in antithrombotic treatment after concomitant ablation surgery in atrial fibrillation patients.

Henrica N A M van Breugel1, Sandro Gelsomino, Pieter W J Lozekoot, Ryan E Accord, Fabiana Lucà, Orlando Parise, Harry J G M Crijns, Jos G Maessen.   

Abstract

OBJECTIVES: We investigated real-life oral anticoagulation (OAC) treatment after surgical ablation and examined its adherence to current recommendations. We also explored factors related to OAC use preoperatively and at follow-up.
METHODS: One hundred and fifteen patients with atrial fibrillation (AF) were evaluated during 12-month follow-up after surgery. Patients were divided into two categories according to the congestive heart failure, hypertension, age ≥75 years, diabetes and prior stroke [or transient ischaemic attack or thromboembolism] (CHADS2) score: 60 patients were assigned to the high-risk group (CHADS2 score ≥2) and 55 to the low-risk group (CHADS2 score ≤1). OAC use was defined as guideline adherent, undertreatment or overtreatment.
RESULTS: Baseline overall guideline adherence was 62%. OAC was underprescribed in high-risk patients and overprescribed in low-risk patients (both, P < 0.001). The only factor associated with OAC use after logistic regression analysis were age >75 years (P = 0.01) and preoperative AF > paroxysmal (P = 0.013). Overall guideline adherence at 12-month follow-up showed a trend towards a better adherence in the sinus rhythm (SR) subgroup (74% vs 55%, P = 0.02). OAC was underprescribed in high-risk patients and overprescribed in low-risk patients (both P < 0.001). After logistic regression analysis, preoperative OAC use (P = 0.007) and other indications for OAC (P = 0.01) were predictors of anticoagulation treatment.
CONCLUSIONS: Real-life OAC prescription in AF patients showed a moderate guideline adherence, with high-risk patients being undertreated and low-risk patients being overtreated. These findings stress the importance that antithrombotic treatment in patients undergoing AF surgery needs to be critically re-evaluated.

Entities:  

Keywords:  Ablation surgery; Anticoagulation; Atrial fibrillation

Mesh:

Substances:

Year:  2013        PMID: 24336783      PMCID: PMC3930226          DOI: 10.1093/icvts/ivt522

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  25 in total

Review 1.  Treatment of lone atrial fibrillation: a look at the past, a view of the present and a glance at the future.

Authors:  Sandro Gelsomino; Mark La Meir; Fabiana Lucà; Roberto Lorusso; Elena Crudeli; Ludovico Vasquez; Gian Franco Gensini; Jos Maessen
Journal:  Eur J Cardiothorac Surg       Date:  2012-01-10       Impact factor: 4.191

2.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

Authors:  A John Camm; Paulus Kirchhof; Gregory Y H Lip; Ulrich Schotten; Irene Savelieva; Sabine Ernst; Isabelle C Van Gelder; Nawwar Al-Attar; Gerhard Hindricks; Bernard Prendergast; Hein Heidbuchel; Ottavio Alfieri; Annalisa Angelini; Dan Atar; Paolo Colonna; Raffaele De Caterina; Johan De Sutter; Andreas Goette; Bulent Gorenek; Magnus Heldal; Stefan H Hohloser; Philippe Kolh; Jean-Yves Le Heuzey; Piotr Ponikowski; Frans H Rutten
Journal:  Europace       Date:  2010-10       Impact factor: 5.214

3.  Female gender is a risk factor for stroke and thromboembolism in atrial fibrillation patients.

Authors:  Deirdre A Lane; Gregory Y H Lip
Journal:  Thromb Haemost       Date:  2009-05       Impact factor: 5.249

Review 4.  Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Robert A Guyton; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; L Samuel Wann; Anne B Curtis; Kenneth A Ellenbogen; N A Mark Estes; Michael D Ezekowitz; Warren M Jackman; Craig T January; James E Lowe; Richard L Page; David J Slotwiner; William G Stevenson; Cynthia M Tracy; Valentin Fuster; Lars E Rydén; David S Cannom; Harry J Crijns; Anne B Curtis; Kenneth A Ellenbogen; Jean-Yves Le Heuzey; G Neal Kay; S Bertil Olsson; Eric N Prystowsky; Juan Luis Tamargo; Samuel Wann
Journal:  J Am Coll Cardiol       Date:  2013-04-01       Impact factor: 24.094

5.  2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society.

Authors:  Hugh Calkins; Karl Heinz Kuck; Riccardo Cappato; Josep Brugada; A John Camm; Shih-Ann Chen; Harry J G Crijns; Ralph J Damiano; D Wyn Davies; John DiMarco; James Edgerton; Kenneth Ellenbogen; Michael D Ezekowitz; David E Haines; Michel Haissaguerre; Gerhard Hindricks; Yoshito Iesaka; Warren Jackman; José Jalife; Pierre Jais; Jonathan Kalman; David Keane; Young-Hoon Kim; Paulus Kirchhof; George Klein; Hans Kottkamp; Koichiro Kumagai; Bruce D Lindsay; Moussa Mansour; Francis E Marchlinski; Patrick M McCarthy; J Lluis Mont; Fred Morady; Koonlawee Nademanee; Hiroshi Nakagawa; Andrea Natale; Stanley Nattel; Douglas L Packer; Carlo Pappone; Eric Prystowsky; Antonio Raviele; Vivek Reddy; Jeremy N Ruskin; Richard J Shemin; Hsuan-Ming Tsao; David Wilber
Journal:  Heart Rhythm       Date:  2012-03-01       Impact factor: 6.343

6.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.

Authors:  B F Gage; A D Waterman; W Shannon; M Boechler; M W Rich; M J Radford
Journal:  JAMA       Date:  2001-06-13       Impact factor: 56.272

7.  A prospective randomized multicenter comparison on health-related quality of life: the value of add-on arrhythmia surgery in patients with paroxysmal, permanent or persistent atrial fibrillation undergoing valvular and/or coronary bypass surgery.

Authors:  H N A M Van Breugel; F H M Nieman; R E Accord; G A P G Van Mastrigt; J F M A Nijs; J L Severens; R Vrakking; J G Maessen
Journal:  J Cardiovasc Electrophysiol       Date:  2009-11-17

Review 8.  Anatomical basis of minimally invasive epicardial ablation of atrial fibrillation.

Authors:  Sandro Gelsomino; Domenico Corradi; Roberto Lorusso; Orlando Parise; Sergio Callegari; Emilio Macchi; Jos Maessen; Mark La Meir
Journal:  Eur J Cardiothorac Surg       Date:  2012-10-30       Impact factor: 4.191

9.  Real-life anticoagulation treatment of atrial fibrillation after catheter ablation: Possible overtreatment of low-risk patients.

Authors:  Nikolaos Dagres; Gerhard Hindricks; Hans Kottkamp; Philipp Sommer; Thomas Gaspar; Kerstin Bode; Arash Arya; Loukianos S Rallidis; Dimitrios Th Kremastinos; Christopher Piorkowski
Journal:  Thromb Haemost       Date:  2009-10       Impact factor: 5.249

10.  Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years.

Authors:  Daniela Poli; Emilia Antonucci; Elisa Grifoni; Rosanna Abbate; Gian Franco Gensini; Domenico Prisco
Journal:  J Am Coll Cardiol       Date:  2009-09-08       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.